Institute of Radiological Protection and Nuclear Safety, France
For 30 years, he has been developing gene and
cell therapy using non-human primates, immune-tolerant mice and rats to protect
against the side effects of radiation. He collaborates with clinicians to
develop strategies for treatment of patients after radiotherapy overexposures.
He has participated in the first establishment of proof of concept of the
therapeutic efficacy of Mesenchymal stem cells (MSCs) for the treatment of
hematopoietic deficit, radiodermatitis and over dosages of radiotherapy. He has
contributed to the first reported correction of deficient hematopoiesis in
patients (graft failure and aplastic anemia) thanks to intravenous injection of
MSCs restoring the bone marrow microenvironment, mandatory to sustain
hematopoiesis after totl body irradiation. He is scientific investigator of
Clinical phase II trial evaluating the efficacy of systemic MSC injections for
the treatment of severe and chronic radiotherapy-induced abdomino-pelvic
complications refractory to standard therapy